Determination of azasetron hydrochloride in rabbit plasma by liquid chromatography tandem mass spectrometry and its application

Biomedical Chromatography

Volumn 25, Issue 10, 2011, Pages 1107-1111

  Lin, Guanyang ^a   Ma, Jianshe ^b   Zhu, Jiayin ^b   Yang, Xuezhi ^a   Hu, Lufeng ^a   Wang, Xianqin ^b  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Azasetron hydrochloride; LC MS MS; Pharmacokinetics; Plasma

Indexed keywords

ELECTROSPRAY IONIZATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; POSITIVE IONS; PRECIPITATION (CHEMICAL); TRICHLOROACETIC ACID;

AZASETRA HYDROCHLORIDE; INTERNAL STANDARDS; ITS APPLICATIONS; LC-MS-MS; LC.MS/MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; RABBIT PLASMAS; SELECTIVE LIQUID CHROMATOGRAPHY; STANDARD PROTEINS;

PHARMACOKINETICS;

AZASETRON; DOXAPRAM; TRICHLOROACETIC ACID;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG STRUCTURE; ELECTROSPRAY; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; RABBIT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

ORYCTOLAGUS CUNICULUS;

EID: 80052522677     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1578     Document Type: Article

References (8)

1. Deng P, Zhong D and Chen X. Determination of tropisetron in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2009; 49: 848-852.
2. Haga K, Inaba K, Shoji H, Morimoto Y, Fukuda T and Setoguchi M. The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis. Japanese Journal of Pharmacology 1993; 63: 377-383.
3. Hayakawa T, Sato M, Konaka M, Makino A, Hirohata T, Totsu S, Wada Y, Sato H, Inotsume N, Fujita A and Sekine K. Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients. Gan To Kagaku Ryoho 2006; 33: 633-638.
4. Kimura E, Niimi S, Watanabe A and Tanaka T. Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho 1997; 24: 855-859.
5. Moriyama Y, Arimori K and Nakano M. Absorption characteristics of azasetron from rectal and oral routes in rabbits. Biological and Pharmaceutical Bulletin 1997; 20: 701-703.
6. Sakamori M, Takehara S and Setoguchi M. High affinity binding of Y-25130 for serotonin 3 receptor. Nippon Yakurigaku Zasshi 1992; 100: 137-142.
7. Tsukagoshi S. Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist. Gan To Kagaku Ryoho 1999; 26: 1001-1008.
8. Yun MJ, Kim YH and Kim AR. Comparison of azasetron and ondansetron for preventing postoperative nausea and vomiting in patients undergoing gynecological laparoscopic surgery. Yonsei Medical Journal 2010; 51: 88-92.